RECURRENT LUNG NON-SMALL CELL CARCINOMA

This early-stage study is testing the safety of a personalized vaccine designed to train a patient's immune system to attack their specific cancer. It is for adults with advanced breast cancer, melanoma, or non-small cell lung cancer that has continued to grow despite standard tr…

This study is testing a new oral drug, S241656, alone and in combination with other cancer therapies. It aims to find a safe and effective dose for adults with advanced cancers, including lung, pancreatic, and colorectal cancers, that have specific genetic mutations like KRAS or …

This study is for people with advanced non-small cell lung cancer that has worsened after initial chemotherapy and immunotherapy. It compares the current standard two-drug treatment (docetaxel and ramucirumab) against that same treatment plus a third drug called cemiplimab, which…

This study is testing if a daily pill called osimertinib can help control advanced non-small cell lung cancer that has a specific genetic change called an EGFR exon 20 insertion. It is for adults whose cancer has worsened after at least one prior treatment. The main goal is to se…

This study is testing two different combinations of targeted drugs for people with advanced non-small cell lung cancer that has specific genetic changes (EGFR and MET) and has stopped responding to a common treatment. The trial will compare whether adding a third drug (ramuciruma…

This study is testing if adding a second drug, ramucirumab, to the standard drug tepotinib works better for people with advanced non-small cell lung cancer that has a specific genetic change called a MET exon 14 skip. The goal is to see if the combination can better control the c…

This study is testing if a new drug, SX-682, works better when given with an existing immunotherapy drug (pembrolizumab) for people with advanced non-small cell lung cancer that has spread or come back. The goal is to see if this combination can help the body's immune system figh…

This is an early safety study testing a new type of personalized immune cell therapy for people with advanced non-small cell lung cancer that has spread to the lining of the chest. Doctors will collect a patient's own immune cells, modify them in a lab to target a specific protei…

This early-stage trial is testing a new combination of two immunotherapy drugs, PBF-1129 and nivolumab, for people with advanced non-small cell lung cancer that has returned or spread. The main goal is to find the safest dose and understand the side effects. Researchers also want…

This early-stage study is testing a new combination of two drugs, vismodegib and atezolizumab, for adults with advanced non-small cell lung cancer that has come back or spread. The main goal is to find the safest dose and understand the side effects of using these drugs together.…

This study aims to learn how advanced lung cancer responds to a combination of chemotherapy, immunotherapy, and radiation by closely watching changes on PET/CT scans. It will enroll 80 patients with stage IV non-small cell lung cancer who are starting this standard treatment. The…

This study aims to collect tumor tissue samples from patients with various cancers to test a new diagnostic platform called Elephas. The goal is to see how accurately this tool can predict whether patients will respond to immunotherapy treatments before they begin. Researchers wi…